journal article·2023-10Open access

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion

Mengdan Wu, Wei Li, Sheng Lin, Jiaqi Fan, Lele Cui, Yijuan Xiang, Kaiyu Li, Linwei Tang, Yanping Duan, Zimin Chen, Fanli Yang, Weiwei Shui, Guangwen Lu, Ying Lai

Advanced Science· Volume 10· Issue 28

Abstract

Abstract The receptor‐binding domain (RBD) of spike recognizing the receptor angiotensin‐converting enzyme 2 (ACE2) initiates membrane fusion between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and cell membrane. Although the structure of the RBD_ACE2 complex has been well studied, its functional mechanism in membrane fusion is still not fully understood. Here, using an in vitro cell–vesicle content‐mixing assay, it is found that the cleavage at the S2’ site by thrombin (Thr) protease strongly accelerates membrane fusion, compared to that of cleavage at the S1/S2 site by PreScission (3C) protease. Moreover, mutations at the RBD_ACE2 interface resulted in a positive correlation between binding affinity and fusion probability. In both the cell–vesicle and cell–cell fusion assays, by crosslinking two membranes via the neutravidin (NTV)_biotin interaction or complementary DNA strands, it is found that spike drives membrane fusion in the absence of ACE2, and a suitable distance between two membranes is critical for spike‐mediated membrane fusion. Finally, unsuitable membrane crosslinkers significantly inhibited the fusion probability in the presence of ACE2. Taken together, the results suggest that the RBD_ACE2 complex may act as a crosslinker to bridge the viral and cell membranes at a suitable distance, which is critical, but also substitutable for spike‐mediated SARS‐CoV‐2 entry.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Lipid Membrane Structure and Behavior · COVID-19 Clinical Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Clinical Research Center for Geriatrics State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan 610041 China

West China Hospital Emergency Department State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan 610041 China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1038/s41580-021-00418-x10.1038/s41580-021-00418-x ↗
2. 10.1016/j.cell.2020.02.05810.1016/j.cell.2020.02.058 ↗
3. 10.1038/s41586-020-2665-210.1038/s41586-020-2665-2 ↗
4. 10.1126/science.abb998310.1126/science.abb9983 ↗
5. 10.1073/pnas.030644610110.1073/pnas.0306446101 ↗
6. 10.1038/s41594-019-0334-710.1038/s41594-019-0334-7 ↗
7. 10.1073/pnas.211140011910.1073/pnas.2111400119 ↗
8. 10.15252/embj.202010740510.15252/embj.2020107405 ↗
9. 10.1073/pnas.200313811710.1073/pnas.2003138117 ↗
10. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
11. 10.15252/embj.202110894410.15252/embj.2021108944 ↗
12. 10.1038/s41467-020-17371-610.1038/s41467-020-17371-6 ↗
13. 10.1038/s41586-020-2772-010.1038/s41586-020-2772-0 ↗
14. 10.1126/sciadv.abe557510.1126/sciadv.abe5575 ↗
15. 10.1016/j.cell.2020.03.04510.1016/j.cell.2020.03.045 ↗
16. 10.1038/s41586-020-2179-y10.1038/s41586-020-2179-y ↗
17. 10.1073/pnas.211119911910.1073/pnas.2111199119 ↗
18. 10.1126/sciadv.abk222610.1126/sciadv.abk2226 ↗
19. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
20. Marcink T. C. · A. Moscona · 2022 · 8
21. 10.1126/science.abb276210.1126/science.abb2762 ↗
22. 10.1038/s41591-021-01285-x10.1038/s41591-021-01285-x ↗
23. 10.1038/s41392-021-00756-410.1038/s41392-021-00756-4 ↗
24. 10.7554/eLife.7065810.7554/eLife.70658 ↗
25. 10.1038/s41579-021-00573-010.1038/s41579-021-00573-0 ↗
26. 10.15252/embj.2010511410.15252/embj.20105114 ↗
27. 10.3390/microorganisms911233110.3390/microorganisms9112331 ↗
28. 10.1128/JVI.78.11.5913-5922.200410.1128/JVI.78.11.5913-5922.2004 ↗
29. 10.1038/s41422-020-00460-y10.1038/s41422-020-00460-y ↗
30. 10.1016/j.jinf.2020.02.02610.1016/j.jinf.2020.02.026 ↗
31. 10.1038/s41392-020-00426-x10.1038/s41392-020-00426-x ↗
32. 10.1007/s12038-017-9676-710.1007/s12038-017-9676-7 ↗
33. 10.1016/j.devcel.2021.09.01610.1016/j.devcel.2021.09.016 ↗
34. 10.1073/pnas.220951411910.1073/pnas.2209514119 ↗
35. 10.3390/clinpract1104009310.3390/clinpract11040093 ↗
36. 10.1111/joim.1347810.1111/joim.13478 ↗
37. 10.1016/j.antiviral.2020.10474210.1016/j.antiviral.2020.104742 ↗
38. 10.1021/jacs.1c0543510.1021/jacs.1c05435 ↗
39. 10.15252/embj.202010605710.15252/embj.2020106057 ↗
40. 10.1038/emboj.2012.5710.1038/emboj.2012.57 ↗
41. 10.1016/j.celrep.2021.10884210.1016/j.celrep.2021.108842 ↗
42. Brevini T. · Nature · 2022
43. 10.1016/j.cell.2020.04.00410.1016/j.cell.2020.04.004 ↗
44. 10.1038/s41467-021-27893-210.1038/s41467-021-27893-2 ↗
45. 10.1038/s41586-022-04474-x10.1038/s41586-022-04474-x ↗
46. 10.1038/s41586-020-2599-810.1038/s41586-020-2599-8 ↗
47. 10.1038/s41467-022-33209-910.1038/s41467-022-33209-9 ↗
48. 10.1016/j.cell.2021.12.03310.1016/j.cell.2021.12.033 ↗
49. 10.1186/s12967-020-02520-810.1186/s12967-020-02520-8 ↗
50. 10.1016/j.cell.2022.06.00510.1016/j.cell.2022.06.005 ↗
51. 10.7554/eLife.0059210.7554/eLife.00592 ↗
52. 10.1021/la901676e10.1021/la901676e ↗